The assessment discusses 58 peptides in various clinical phases, indicating a robust pipeline of peptide therapies targeting PPIs. Co-formulation with other permeation enhancers, enzyme inhibitors, and hydrogels have also been used to enable the oral administration of other peptide medicine, including octreotide and insulin, that are now in clinical trials280,281. https://romaint343tgq6.oneworldwiki.com/user